Lisa Ricciardi, President and CEO of Cognition Therapeutics, was recently a guest on Benzinga's All-Access.<br /><br />Cognition Therapeutics is a neuroscience company that is developing oral medications to treat neurodegenerative disorders, with recent breakthroughs in the treatment of dementia with Lewy bodies (DLB) and Alzheimer's disease.<br /><br />Ms. Ricciardi was on the program to discuss exciting developments coming in 2025.
